左西孟旦联合重组人脑利钠肽在急性心力衰竭中的应用  

Application of Levosimendan Combined With Recombinant Human Brain Natriuretic Peptide in Acute Heart Failure

作　　者：王天镜 逄晓玲[1] 朱杰[1] 陈达[1] 张洪颖[1] 刘丹[2] 高雪萌 周秀华[2] WANG Tianjing;PANG Xiaoling;ZHU Jie;CHEN Da;ZHANG Hongying;LIU Dan;GAO Xuemeng;ZHOU Xiuhua(Department of Emergency,The Fourth Affiliated Hospital of China Medical University, Shenyang Liaoning 110032, China;Department of Critical Care Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang Liaoning 110032, China;The Second Department of Clinical Medicine, China Medical University, Shenyang Liaoning 110001, China)

机构地区：[1]中国医科大学附属第四医院急诊科,辽宁沈阳110032 [2]中国医科大学附属第四医院重症医学科,辽宁沈阳110032 [3]中国医科大学临床二系,辽宁沈阳110001

出　　处：《中国继续医学教育》2019年第21期124-127,共4页China Continuing Medical Education

基　　金：国家自然科学基金(81700266)

摘　　要：目的探讨左西孟旦联合重组人脑利钠肽治疗急性心力衰竭的临床治疗效果。方法将我院急诊内科收治的急性心力衰竭患者40例随机分为对照组与观察组,每组各20例。对照组给予左西孟旦治疗;观察组给予左西孟旦与重组人脑利钠肽联合治疗。选取治疗前及治疗72h后作为观察时点,比较两组患者疗效与NT-proBNP水平、LVEF值、LVEDD指标。结果观察组疗效(95.0%)优于对照组(70.0%),差异具有统计学意义(P<0.05)。两组患者治疗后NT-proBNP均显著降低,LVEF值均显著升高,差异具有统计学意义(P<0.05)。观察组患者的NT-proBNP低于对照组,LVEF高于对照组,差异均具有统计学意义(P<0.05)。结论左西孟旦联合重组人脑利钠肽治疗可显著提高急性心衰疗效,改善患者心功能。Objective To explore the clinical effect of levosimendan combined with recombinant human brain natriuretic peptide in the treatment of acute heart failure. Methods 40 patients with acute heart failure admitted to the emergency department of internal medicine in our hospital were randomly divided into control group and observation group, 20 cases in each group. The control group was treated with levosimendan. The observation group was treated with levosimendan combined with recombinant human brain natriuretic peptide. Before treatment and 72 hours after treatment were selected as observation points. The curative effect, NT-proBNP level, LVEF value and LVEDD index were compared between the two groups. Results The curative effect of the observation group (95.0%) was better than that of the control group (70.0%). The difference was statistically significant (P < 0.05). After treatment, NT-proBNP decreased significantly and LVEF increased significantly in both groups (P < 0.05). The NT-proBNP of the observation group was lower than that of the control group, and the LVEF of the observation group was higher than that of the control group (P < 0.05). Conclusion Levosimendan combined with recombinant human brain natriuretic peptide can significantly improve the clinical efficacy and improve cardiac function in patients with acute heart failure.

关 键 词：急性心力衰竭 左西孟旦 重组人脑利钠肽 临床疗效 N-脑钠肽前体 左室射血分数 左室舒张末期内径 

分 类 号：R541[医药卫生—心血管疾病]